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INTRODUCTION
Cystic fibrosis (CF) patients have complex 
medication regimens and undergo frequent 
hospital admissions. Each of which is an 
opportunity for medication errors (ME). 
On admission, the hospital pharma-
cist performs medication reconciliation 
to clarify and document drug histories. 
During this process, we identified ME in previous 
discharge prescriptions (DPs), with resultant 
confusion regarding the appropriate treat-
ment regimen. This finding necessitated 
reoptimization of medication at admis-
sion to ensure that no harm had occurred 
as a consequence. Electronic prescribing 
reduces ME,1 and ours lack a computer-
ized order entry system. Therefore, medi-
cations need to be typed for dose regimes.
Errors are perhaps inevitable, but prompt 
and effective identification (with subsequent cor-
rection) of contributory factors (a learning culture) will 
prevent their repetition.2,3 In the pediatric CF context, 
with the combination of frequently adjusted polyphar-
macy (for disease evolution, changes to treatment guide-
lines, or simply due to physical growth or maturity) and 
multiple hospital admissions, this process of learning 
from errors is particularly pertinent. Formulation infor-
mation is essential in pediatrics, liquid forms with differ-
ing concentrations are widely used, and parents tend to 
recall liquid volumes rather than actual milligrams or mi-
crogram doses, risking 10-fold, or greater dosing errors.
Additionally, inadvertent dispensing of alternate brands 
may risk both compliance and efficacy, as equivalent 
strength products from different sources may have mark-
edly differing palatability and even physical properties. 
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Additional risks stem from the frequent use of pediatric 
formulations, as well as off-label or unlicensed medica-
tions, compounding errors, and the fact that junior med-
ical staff does most of the prescribing, many of whom 
work only briefly within the CF service. The risk of ME in 
pediatric CF is, therefore, particularly high.
There is increasing evidence that the involvement of the 
pharmacists in interdisciplinary teams has a positive influ-
ence on the quality of medication use and patient safety by 
rationalizing the pharmacotherapy and reducing ME and 
drug-related problems in these settings.4–12 Furthermore, 
proactive participation of pharmacist conducting medi-
cation reconciliation at admission and discharge is useful 
to identify, prevent, and resolve drug-related problems.13
Previous work has examined ME in different patient 
populations,2 but few have involved CF patients.14,15
The main objective of this study was to improve the quality 
of the DP for CF patients admitted to the hospital to receive IV 
antibiotics, using safety indicators to drive this improvement.
METHODS
We performed this study in a specialist pediatric CF 
center in a London children’s hospital. Improvement 
actions followed an initial retrospective longitudinal ob-
servational descriptive study of 24 months. We imple-
mented safety strategies in the DP process, including a 
prospective longitudinal quasi-experimental study of 8 
months. Included case notes came from subjects 0–16 
years of age with a diagnosis of CF who had been admit-
ted to the pediatric respiratory ward to receive intrave-
nous therapy. The Clinical Effectiveness Unit sponsored 
the study at the host hospital; the study was viewed as a 
service evaluation and quality improvement with no di-
rect patient impact and thus did not come under ethics 
review board jurisdiction.
Figure 1 depicts how we conducted the study; bold text 
indicates sources used to detect DPs, opportunities for im-
provement, and target-optimized prescribing.
Fig. 1. Flowchart process identifying improvements opportunities, selecting and implementing strategies and safety actions, and 
sources of information used to evaluate therapies prescribed at hospital discharge. ** Exhaustive reconciliation: of drug histories 
using patient’s drugs, homecare prescription, primary care prescription, and previous discharge letter or last clinic letter. Prompt 
chart: designed and attached in drug chart with emphasis on inhaled nebulizers to be reviewed at discharge time. Interventions 
monitoring: during a hospital stay. Drug listing: at discharge pharmacist could help to list the drugs that would need to be continued. 
Communication: with careers of any changes, nurses, and prescribers. EPR indicates electronic prescribing in retrospective phase; 
EPP, electronic prescribing in prospective phase.
Chorro-Mari et al • Pediatric Quality and Safety (2019) 4:5;e208 www.pqs.com
3
We reviewed DPs for the following factors:
 1. The presence of the weight of the child in the pre-
scription.
 2. The presence of any clinically indicated medicines.
 3. Pharmacokinetic aspects (drug interactions, dose 
adjustment for CF/other drugs/pathology).
 4. Optimized dose and frequency for age, anthropom-
etry, hepatic impairment, etc.
 5. Treatment duration, start, stop, and efficacy/safety 
review dates.
 6. Route of administration (oral, IV, nebulized, rectal, etc.).
 7. Pharmaceutical formulation and specific brand 
where necessary.
 8. Allergy information documented.
We assessed the quality of the DPs according to the 6 
Rights (6R) of medication administration: drug, dose, fre-
quency, duration of treatment, route of administration, 
and pharmaceutical form. We calculated these quality 
Indicators by quantifying the number of prescriptions 
with correct completion for each of the 6R and then di-
viding this figure by the total number of prescriptions 
written during the period under scrutiny. The aspira-
tional target value given was 90% for each one of the 6R. 
Additionally, we defined a global quality indicator that 
measured all the 6R that appeared correctly in the DP. For 
this quality indicator, the standard value given was 50%.
The classification of ME considered for quality indica-
tors is shown in Table 1.
We categorized the severity of the ME depending on the 
potential pharmacotherapy morbidity, using a scale from 
1 to 5 in which describes higher severity while going up 
the values. Grade 1: ME that would not cause any harm 
or would be reversible (with no vital signs changes) but 
monitoring would be required. Grade 2: ME that would 
cause reversible harm (with no vital signs changes) but 
modification of treatment would be required. Grade 3: 
ME that would cause reversible harm and would require 
additional treatment, prolonged hospital stay. Grade 4: 
ME causing irreversible harm or disability. Grade 5: ME 
that would cause the patient’s death.
Figure 2 represents the strategies to improve DPs and 
safety actions that the multidisciplinary team agreed to 
and implemented for CF patients in the prospective phase.
Table 1. Definition of the Type and Subtype Classification of the Medication/Prescribing Errors
Committed: Incorrect Information in Prescription Omitted: Absence of Specific Information in Prescription
Drug When the drug prescribed is either: • A drug mentioned in the discharge letter medication list is 
not mentioned in the electronic discharge or vice versa;
• Inappropriate for the specified indication; • A part of the patient’s usual drug regimen is inadvertently 
omitted during admission to or discharge from hospital. 
Examples: nebulized mucolytics, insulin, voriconazole
• Continued beyond intended end date; • Failure to list the patient’s usual “rescue” antibiotics on the 
DP to facilitate access in primary care via repeat prescrip-
tion. Examples: co-amoxiclav, ciprofloxacin.
• Subject to Interactions/variable absorption that may affect  
efficacy or adverse reaction profile (eg, concomitant administra-
tion of itraconazole and proton pump inhibitors).
Dose • When the dose is prescribed by volume rather than mass  
(exclude AquADEKs/DEKAS, Sytron and Lactulose). Or when 
incorrect units are used.
• Failure to cite dose or units in the prescription.
When the prescribed dose falls outside a 20% tolerance of the 
age/weight-appropriate dose with reference to the admission 
weight, the local CF dosing guidelines and the British National 
Formulary for children (BNFc).
• Citing “as directed” (excluding pancreatic enzyme prepara-
tions, creams/ointments or medication that was not related 
to CF or any associated pathology).
Frequency • Any frequency higher than or less than 20% of what would be 
expected for that age/weight from the references used were 
considered mistakes.
• Omitting frequency of dose required.
• Stating frequency as “when required” (excluding pancreatic 
enzyme preparations, creams/ointments or medication that 
was not related to CF or any associated pathology).
Duration When the duration prescribed for a drug is incorrect according  




• Alternating nebulized treatments;
• New medication prescribed (if there was any review date 




• Wrong pharmaceutical form prescribed; • When >1 preparation is licensed in the market (referring 
mainly to liquid preparations) and the pharmaceutical form 
is absent (excluded for liquid preparations with a unique 
strength/formulation)
• A better preparation for adherence is available at similar cost; • The type of nebulizer/inhaler/insulin prescribed is not stated.
• Prescription of a more expensive pharmaceutical form without 
justification;
• Inconsistent pharmaceutical forms in the same prescription for 
other drugs;
• Prescription of liquids for a patient who tolerates tablets  
(excluding itraconazole—liquid is better absorbed).
Route of 
administration
• Incorrect route of administration; • Administration route is not stated.
• Stated route of administration is inconsistent with that of other 
medicines that would normally be administered via the same 
route.
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Continuous and categorical variables were analyzed 
using appropriate statistical tests concerning the type of 
variable and its distribution. Quantitative data followed 
a normal distribution (Kolmogorov-Smirnov test applied) 
and was analyzed by descriptive statistics (ie, mean, SD, 
and range). We used the Student t test when comparing 
2 data sets and Analysis of Variance when comparing >2 
samples. Chi-square test was applied to compare propor-
tions. We present categorical data as absolute frequencies 
and relatives (proportions or percentages) with a 95% CI 
(Table 2).
RESULTS
We included a total of 42 children, 16 (38%) males and 
26 (62%) females, mean age 9.80 years + 4.43 (range 
1–17) in the retrospective study. The prospective study 
comprised 35 patients, 14 (40%) males and 21 (60%) 
females, mean age 10.11 years + 3.89 (range 3–16). The 
mean number of admissions per patient was 2.43 + 2.04 
(100 total discharges, range 1–8) in the retrospective 
phase and 1.60 + 0.8 (55 total discharges, range 1–4) in 
the prospective phase. Table 2 describes the characteristics 
of the discharged patients included in both phases of the 
study, type of ME (omitted/committed) with classification 
according to the 6R, and rates of ME. During medicines 
reconciliation on admission, a 78% of ME detected cor-
responded to Grade 1 and 22% of ME caused reversible 
harm (Grade 2). At discharge, 93% of ME were classified 
as Grade 1 and 7% as Grade 2. There were no Grade 3 
or above ME.
Figure 3 shows the values of each quality indicator of 
the 6R and the global indicator obtained in both phases 
of the study. Statistical P-value when compared quality 
indicator values obtained in retrospective and prospective 
studies are also shown.
DISCUSSION
Previous research has acknowledged that pediatric 
patients are at risk of encountering ME, including pre-
scribing errors.16
A general definition of a prescribing error was devel-
oped for pediatrics by Ghaleb et al,17 and the following 
factors were considered prescribing errors: (1) failure 
to communicate essential information, (2) transcription 
errors from one prescription to another and the use of 
drugs, (3) formulations, and (4) inappropriate doses.
Few studies evaluate the incidence of prescribing errors 
in the CF pediatric population, despite the elevated risk 
described in the introduction. There have been several UK 
studies of pharmacist-led interventions, but few involve 
pharmacist evaluation of CF DPs.
Huynh et al. evaluated the discrepancies of medicines 
reconciliation in children at the time of hospital admis-
sion finding that 45% of the children had at least 1 un-
intentional medication discrepancy. No single source of 
information provided all the relevant details of a patient’s 
medication history. Parents/carers provided the most ac-
curate details of a patient’s medication history in 81% of 
cases. It is not surprising that children admitted to hospi-
tals are at risk of harm from unintended medication dis-
crepancies at the transition of care from the community 
to the hospital.18
Therefore, children on excessive polytherapy, are vul-
nerable to potential transitional care ME, especially if 
there is a low threshold to hospital admissions such as in 
CF or other complex diseases with associated pathologies.
Fig. 2. Safety actions and improvement strategies.
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A possible cause/risk of error is that CF patients on 
admission for antibiotic IV therapy tend to stop their neb-
ulized antibiotics and in most of the cases patients are 
expected to restart them after the IV course. However, 
when the patient is due to be discharged, the information 
regarding restarting treatment with the nebulized antibi-
otics and prophylactic antibiotics (if they were on them 
before admission) can be missed, with the possibility of 
creating confusion to parents/carers, especially when the 
burden of responsibility for the child’s CF regimen resides 
with a specific family member.
Moreover, the pediatric population is notable for 
wide-ranging weight, physiological, and emotional matu-
rity.19 Unfortunately, child-friendly drug formulations re-
main scarce and often pharmacists must find unlicensed/
off license alternatives. Crushing and dispersing tablets is 
common practice in the pediatric setting, with potential 
impacts on absorption and adheres, as palatability and 
can be a problem.
The quality of a prescription for any pediatric patient 
should be accepted with higher standards to that of a 
normal prescription. Key among the multiple factors that 
reduce compliance with CF therapy is the problem of 
patients receiving conflicting information.20 Novel treat-
ments mean the pediatric CF population is ever more vul-
nerable to ME, and thus, this work is both important and 
timely.
The professionals involved in prescribing are diverse, 
for instance: junior doctors (ward prescribing, discharge 
summaries); senior doctors/consultants (primarily in the 
outpatient clinic); CF-independent prescribing nurse/
pharmacists (clinic letters and homecare prescribing); ge-
neral practitioners (acute and repeat prescriptions); com-
munity pharmacists (prescriptions and over the counter 
products); and ward pharmacists. This large and varied 
population of involved professionals may have a different 
understanding of and training in CF prescribing quality.
Smeulers et al21 reviewed the literature to identify evi-
dence-based quality indicators for safe in-hospital med-
ication preparation and administration, and although 
the current study is based on prescribing indicators, the 
quality indicators identified by Smeulers were an excel-
lent starting point to develop prescribing specific quality 
indicators for medication safety. In the current study, we 
defined the 6R of prescribing, making a further distinc-
tion into committed or omitted errors. We established ar-
bitrary aspirational standards for each quality indicator, 
with targets dependent upon the expectations of the in-
vestigator team.
The advantage of the prospective study was that the 
committed errors of dose and frequency and their poten-
tial impact were discussed with the prescribers. Action 
was taken to rectify them by contacting the parents di-
rectly if they had already left the hospital and making 
sure that the error would not reach the administration 
stage. (eg, azithromycin would not be given 3 times a 
day but 3 times a week, which would be quite unlikely 
as this was part of their regular medication and parents 
were well aware of their children’s treatment). Also, we 
encountered some practical obstacles in the pursuit of this 









Age (y); mean ± SD (range) 10.5 + 3.9 (1–17) 10.2 + 3.9 (2–16) 0.647
Hospital stay (d); mean ± SD (range) 12.8 + 4.2 (2–22) 13.8 + 2.4 (6–21) 0.106
N drugs on discharge; mean ± SD (range) 13.4 ± 3.9 (6–27) 14 + 4.4 (3–26) 0.383
Gender    
  Male n (%) 31 (31.00) 19 (34.55) 0.652
Associated pathologies n (%)    
  • Pancreatic insufficient 98 (98.00) 51 (92.73) 0.105
  • GORD 73 (73.00) 37 (67.27) 0.454
  • CF-related diabetes 31 (31.00) 16 (29.09) 0.805
  • Liver disease/gallstones 17 (17.00) 18 (32.73) 0.026*
  • Other 53 (53.00) 22 (40.00) 0.122
Reason for admission n (%)    
  • Infective exacerbation 45(45.00) 35 (63.64) 0.027*
  • Elective 55 (55.00) 20 (36.36) 0.027*
Total N drugs reviewed 1,343 822 —
Total N ME identified 148 135  
  Committed errors n (%) 78 (52.70) 19 (14.07) <0.001*
  Omitted errors n (%) 70 (47.30) 116 (85.93) <0.001*
Type of ME    
  Drug n (%) 38 (25.68) 5 (3.70) <0.001*
  Dose n (%) 35 (23.65) 4 (2.96) <0.001*
  Frequency n (%) 3 (2.03) 8 (5.93) 0.091
  Duration n (%) 25 (16.89) 2 (1.48) <0.001*
  Pharmaceutical form n (%) 44 (29.73) 31 (22.96) 0.198
  Route of administration n (%) 3 (2.03) 85 (62.96) <0.001*
Rate of ME expressed per patient 3.54 3.86 0.895
Rate of ME expressed per discharge 1.49 2.46 0.607
Rate of ME expressed per 100 drugs prescribed 11.06 16.4 <0.001*
* Denotes a statistical significant difference, P < 0.05.
GORD indicates gastro esophageal reflux disease.
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work such as weekends discharges written by nonrespira-
tory specialists (as they are not necessarily aware of the 
need of restarting medication held during the admission). 
The addition of pharmaceutical form preferred by the pa-
tient in the DP was helpful to ensure there would be con-
tinuity of the same form in primary care.
The potential severity of the errors was higher on ad-
mission than at discharge, and since the CF department 
has a fluent communication between the team, together 
with the culture of sharing mistakes, the tendency of these 
prescribing errors feels to be minimized as the time is 
passing since the team is gaining greater experience.
The pediatric pharmacy team is known to the CF de-
partment, and this relationship permits closer communi-
cation and understanding of the CF patients drug therapy 
needs. This familiarity is reflected in the way that phar-
macists handle DPs: ensuring accuracy of usual patient’s 
pharmaceutical forms were written down in the DP as 
well as getting the discharge medication in an optimized 
timely manner.
Our aspirational target was 90% for each 6R indi-
cator in each DP. Assuming that 90% accuracy target 
would equate each of the 6R, the global indicator aimed 
50% target for the overall quality of prescription in CF 
children.
We evaluated the quality indicators retrospectively in 
the first phase of the study. We implemented a new com-
puter system for prescribing at discharge during the final 
time of the retrospective analysis. This change drove the 
development of a prescribing prompt card and other 
strategies to improve prescribing quality prospectively.
The strategies implemented aimed to minimize the 
error rate at discharge at the same time as ensuring an 
accurate drug history to serve as a reliable source for fu-
ture reference.
One of the limitations of the study was that the pro-
spective phase had to be performed in a different pre-
scribing system from the retrospective phase. The new 
system showed an important procedural error in some 
prescribing process of the 6R. Each drug had to be man-
ually entered (we did not count minor typographic errors 
as drug errors); the frequency field was a checkbox type, 
with no room to edit or expand on specifics of timing, etc; 
there was no unique database field for route of administra-
tion or pharmaceutical form and thus no built-in prompt 
for prescribers to provide this key information. However, 
the section to enter the dose and treatment duration of 
treatment was comparable to the electronic prescribing 
system used in the retrospective phase, and there was a 
field to annotate any comments made by pharmacy staff, 
which were mostly to clarify duration or review dates of 
treatments (this field was not in the previous system).
The indicators of the drug, dose, and duration showed 
significant improvement (P < 0.05) following the interven-
tion, achieving the quality standard of 90%. The pharma-
ceutical form indicator showed an improvement from the 
retrospective phase results but did not achieve the quality 
standard aimed at 90% (66% versus 74.55% prospec-
tively). By comparison, the frequency indicator deterio-
rated following the intervention (97% versus. 85.45%, 
P = 0.008), the reasons for which are unclear. There was 
also a deterioration in the route of administration indi-
cator, largely due to information omitted in the computer 
system used in the prospective study. The summary quality 
indicator did not reach the global standard value defined 
of 50%, although there was an overall improvement (P = 
0.009), indicative of a modest benefit from the improve-
ment strategies, and a need for further efforts for change.
Having a computer prescribing system that does 
not prompt users to input complete prescription 
Fig. 3. Quality indicator values in both phases of the study with the standard value indicated in green.
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information challenges prescribers and pharmacists 
in an overloaded work environment. The current UK 
healthcare context is marked by significant inpatient 
bed pressure, with an urgent need to expedite hospital 
discharge. This pressure lends itself to haste in DP, 
with junior doctors reliant on the advice of validating 
ward pharmacists to vouchsafe prescription accuracy. 
Prescription validation is compromised in that medica-
tion reconciliation may not always employ 2 sources of 
confirmation.
The process described should be embedded as part of a 
continuous program of quality improvement, to maintain 
and raise departmental prescribing standards and protect 
patient safety.
As conclusions in this study, specialist pharmacist re-
view of DPs permits the identification of failures in the 
quality of prescriptions in children with CF. The imple-
mentation of safety actions and improvement strategies 
designed in this study contributed to an improvement in 
the prescribing, with an associated reduction in commit-
ted errors. The global quality indicator increased signif-
icantly with the improvement actions in the prospective 
phase, although we did achieve the quality standard goal. 
Continued efforts will drive this indicator to and beyond 
the target. This improvement will occur through more rig-
orous implementation of the identified safety strategies, 
and a rolling program of service evaluation and quality 
improvement using the methodology outlined in this 
work. An adequate complement of well-trained highly 
specialized pharmacists and pharmacy technicians are 
key to this continued improvement in the quality and 
safety of DPs in children with CF.
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